United States drug ad war pits Novo Nordisk against Lilly
Tap title to read story
Novo Nordisk has filed a federal lawsuit in the U.S. District Court for the District of New Jersey accusing Eli Lilly of running deceptive nationwide advertising campaigns for its obesity and diabetes drugs Zepbound and Mounjaro. The complaint, lodged on Tuesday, alleges violations of federal and state false advertising and unfair competition laws, including the Lanham Act. Novo Nordisk claims Lilly used outdated clinical trial data to suggest Zepbound patients lost an average of 50 pounds versus 33 pounds on Novo’s Wegovy, while allegedly comparing a higher Zepbound dose to an older, lower Wegovy dose and omitting newer Wegovy formulations now available.
More context
Timeline
- End of decade Analysts forecast $120 billion market
- Earlier trials Generate weight-loss data for comparisons
- Recent years Novo and Lilly expand GLP-1 portfolios
- Tuesday Novo Nordisk files federal lawsuit
- Tuesday Case assigned to New Jersey district court
- After filing Lawsuit cites Lanham Act violations
- After filing Complaint challenges Lilly’s efficacy claims
- Going forward Court to review advertising evidence
Why it matters
This lawsuit could impact the information you see about obesity and diabetes drugs. If Novo Nordisk wins, it may force Lilly to change its advertising. That means more accurate data for you when choosing a medication. Check with your doctor about the latest drug trials and formulations.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
